论文部分内容阅读
目的探讨吉西他滨联合多西紫杉醇治疗软组织肉瘤的疗效及毒性反应。方法 89例复发转移的晚期软组织肉瘤患者,采用吉西他滨900mg/m2静脉滴注90min,第1、8天;多西紫杉醇75mg/m2,静脉滴注60min,第8天;3周重复。分析肉瘤及5种组织学亚型患者的近期疗效、生存及影响因素。结果可评价近期疗效的82例患者中2例完全缓解,25例部分缓解,总有效率32.9%;平滑肌肉瘤和恶性纤维组织细胞瘤有效率分别为44.4%和40%,与其他组织学亚型之间差异有显著性(P=0.024)。83例患者可评价生存,1年生存率42.2%,2年生存率16.9%。结论吉西他滨联合多西紫杉醇是治疗复发转移晚期软组织肉瘤的有效方案,不同组织学亚型之间存在敏感性差异,毒性可以耐受。
Objective To investigate the efficacy and toxicity of gemcitabine plus docetaxel in the treatment of soft tissue sarcoma. Methods Eighty-nine patients with advanced soft tissue sarcoma who relapsed and metastasized were treated with 900 mg / m2 gemcitabine for 90 min on days 1 and 8, docetaxel 75 mg / m2, intravenously for 60 min on day 8, and repeated for 3 weeks. Analysis of sarcoma and five histological subtypes of patients with short-term efficacy, survival and influencing factors. Results Two of 82 patients who could evaluate the short-term curative effect were completely relieved and 25 patients were partially relieved, with a total effective rate of 32.9%. The effective rates of leiomyosarcoma and malignant fibrous histiocytoma were 44.4% and 40%, respectively. Compared with other histological subtypes The difference was significant (P = 0.024). Eighty-three patients were evaluated for survival, one-year survival 42.2%, and two-year survival 16.9%. Conclusion Gemcitabine combined with docetaxel is an effective regimen for the treatment of advanced soft tissue sarcoma with recurrence and metastasis. There are sensitive differences between different histological subtypes, and the toxicity can be tolerated.